Phase Ib Study of Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM): "The CyBorD-DARA Study"
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2016
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CyBorD-Dara
- 25 Nov 2016 Status changed from not yet recruiting to recruiting.
- 10 Nov 2016 New trial record